Impact of Semaglutide on Cardiovascular Outcomes in Obese Persons
Obesity remains a global health challenge, which is defined as an abnormal or excessive accumulation of body fat to the extent that one’s health may be affected. Obesity increases the risk of various cardiovascular diseases, and semaglutide—a GLP-1 receptor agonist—appears to not only help reduce weight, but aid in improving cardiovascular outcomes as well. Clinical data generally confirms that such treatment may help support bolstered cardiovascular health.

With reduced weight comes reduced cardiovascular risks caused by elevated blood pressure, elevated lipid levels, or markers of inflammation, and semaglutide has been shown to reduce all three. These are especially critical for people with obesity, who are at a much heightened chance of heart attack, stroke, or other cardiovascular events.

In the STEP trials that studied obese patients, participants who were treated with semaglutide not only had significant weight loss but also had changes in cardiovascular risk markers. The findings conclude that semaglutide may potentially assist in reducing cardiovascular morbidity and mortality rates in obese individuals, as the treatment addresses weight management and more.